Sen. J.D. Vance

Maddy summaryThis bill amends the Immigration and Nationality Act to clarify birthright citizenship by adding specific exceptions. It states that children born in the U.S. to parents who are unlawfully present (e.g., undocumented immigrants), serving as diplomats, or engaged in hostile activities (like terrorism) would not automatically gain U.S. citizenship at birth. The law directly affects children of these specific parent categories who are currently covered under current citizenship rules. It codifies existing judicial interpretations but does not change the 14th Amendment's core principle of birthright citizenship for most others.

Maddy summaryThis Senate resolution (SRES 718) expresses the Senate's position that the U.S. government should immediately halt all federally funded gain-of-function research due to safety concerns. It specifically urges Congress to pass the Viral Gain-of-Function Research Moratorium Act (S. 81), which would define such research as work that could enhance a virus's transmissibility or pathogenicity and prohibit federal grants for it. The resolution directly affects research institutions receiving federal funding, including universities and organizations like EcoHealth Alliance, that conduct this type of work. As a non-binding resolution, it calls for legislative action but does not itself impose the moratorium.

Maddy summaryThis resolution designates May 2024 as "Older Americans Month" through a ceremonial Senate action. It does not create new laws or alter existing programs, but rather formally recognizes the contributions and importance of older adults in the U.S. The resolution encourages the public to honor older individuals' achievements, share their wisdom with younger generations, and acknowledge their role as community assets. This designation aligns with the longstanding tradition started by President Kennedy in 1963, which has been observed annually since 1965.

Maddy summaryS 4405, the Natural Gas Tax Repeal Act, repeals Section 136 of the Clean Air Act, which previously provided incentives for reducing methane emissions in the natural gas and petroleum industry. This bill directly affects natural gas and oil companies that participated in the methane emissions reduction program under the repealed section. The bill also rescinds any unobligated funds allocated for that program before its enactment. The legislation removes an existing federal incentive program without creating new taxes or regulations.

Maddy summaryThe Promising Pathway Act 2.0 creates a new FDA pathway for conditional approval of drugs treating rare, progressive, and serious diseases. This allows patients with limited treatment options to access promising new drugs sooner, based on preliminary safety data from Phase 1 trials and effectiveness data from Phase 2 trials (or preliminary evidence for terminal pediatric rare diseases). The law requires drug sponsors to establish observational registries tracking patient outcomes, mandates specific labeling for conditionally approved drugs, and requires private health insurers and federal health care programs to cover these drugs without cost-sharing. Conditional approval is initially granted for 2 years with potential for up to 3 renewals (totaling 8 years), but can be withdrawn if safety data changes or sponsors fail to meet requirements.

Maddy summaryThis joint resolution (SJRES 58) seeks congressional disapproval of a Department of Energy rule establishing new energy efficiency standards for consumer furnaces. It targets the specific rule published in the Federal Register on December 18, 2023 (88 Fed. Reg. 87502), which set requirements for furnace manufacturers. If passed, the resolution would nullify this rule, preventing it from taking effect and requiring the Department of Energy to withdraw the standards. The resolution directly affects furnace manufacturers and consumers by halting the implementation of these new efficiency requirements.

Maddy summaryThis bill, S 1274 (REEF Act), amends the 2020 Railroad Unemployment Insurance payment rules to clarify when certain provisions apply. It removes specific paragraphs and changes the effective date to make the payment rules retroactive, as if they had been in place before the end of the federal COVID-19 national emergency. The change directly affects railroad workers receiving unemployment benefits through the Railroad Unemployment Insurance Account. The key mechanism is adjusting the timing of these payment rules without altering the benefits themselves.

Maddy summarySRES 697 is a commemorative resolution designating the week of May 12-18, 2024, as "National Police Week" in the U.S. Senate. It aligns with the 1962 law authorizing the President to designate this week, honoring law enforcement officers who have died or been injured in the line of duty. The resolution expresses support for officers, recognizes their service in protecting communities, and encourages public observance to honor their mission and sacrifices. It does not create new policies or affect specific groups, as it is purely ceremonial.

Maddy summaryThe Reshape Alternatives to Detention Act of 2024 terminates two programs that allowed certain immigrants to avoid detention (Case Management Pilot and Young Adult Case Management) and prohibits similar alternatives. It mandates GPS tracking for all non-detained immigrants throughout their immigration proceedings - including appeals - and until removal, while requiring biometric data for eligibility in any alternative-to-detention program. The bill also bars participation for immigrants residing in areas that restrict sharing immigration status information with federal authorities (so-called "sanctuary jurisdictions") and mandates strict check-in requirements for the Intensive Supervision Appearance Program.

Maddy summarySJRES 82 is a joint resolution that would block a Food and Drug Administration (FDA) rule regulating laboratory-developed tests (LDTs) - tests created and used within single clinical laboratories without prior FDA review. The rule, published in the Federal Register on May 6, 2024, would have required FDA oversight for these tests before clinical use. If enacted, this resolution would void the rule under the Congressional Review Act, maintaining the current regulatory framework where LDTs operate with minimal federal oversight. It directly affects the FDA's authority over LDTs and clinical laboratories relying on this existing system.